BioPharmSignal logoBioPharmSignal

Biotech News

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026

Praxis Precision Medicines (PRAX)Praxis Precision MedicinesClinical readout

Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026 Praxis to present 3 oral presentations and 12 posters at AAN 2026 Visit Praxis at Booth #2324 for an

Open original release

Related news

PRAXPraxis Precision Medicines2026-04-06 12:00 EST

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

NERVMinerva Neuroscience2026-03-31 20:05 EST

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

ALKSAlkermes plc2026-04-16 11:00 EST

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

PRAXPraxis Precision Medicines2026-04-14 11:30 EST

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

XENEXenon2026-04-07 12:30 EST

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

KTTAPasithea Therapeutics2026-06-30 11:00 EST

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

TEVATeva Pharmaceutical Industries2026-06-18 20:57 EST

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

GHRSGH Research2026-06-04 11:00 EST

GH Research Announces Publication of Phase 2a Postpartum Depression Results

ALKSAlkermes plc2026-04-01 11:00 EST

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

TNXPTonix Pharmaceuticals2026-06-29 11:25 EST

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

View all latest news

Praxis Precision Medicines

Praxis Precision Medicines is a neuroscience company focused on precision approaches to brain disease and movement disorders. Its platform aims to translate genetics and neurobiology into treatment options.

Recent company news

PRAXPraxis Precision Medicines2026-06-01 20:15 EST

Praxis Precision Medicines Provides Vormatrigine Program Update

PRAXPraxis Precision Medicines2026-05-07 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

PRAXPraxis Precision Medicines2026-05-05 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRAXPraxis Precision Medicines2026-05-04 20:01 EST

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

PRAXPraxis Precision Medicines2026-04-14 11:30 EST

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Stock data

Close
315.80 USD
Market cap
7.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States